Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

@article{OBrien2017ClinicalPW,
  title={Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology},
  author={John Tiernan O'Brien and Clive Holmes and Matthew Jones and Roy W Jones and Gill Livingston and Ian G. McKeith and Peter J. Mittler and Peter Passmore and Craig W. Ritchie and Louise Robinson and Elizabeth L. Sampson and John-Paul Taylor and Alan J. Thomas and Alistair Burns},
  journal={Journal of Psychopharmacology},
  year={2017},
  volume={31},
  pages={147 - 168}
}
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A–D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have… 
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress
TLDR
The pharmaceutical compounds that are currently used for the symptomatic treatment of Alzheimer’s disease are addressed and ongoing strategies designed to modify its natural course are discussed.
Memantine for dementia.
TLDR
High-certainty evidence from up to 14 studies in around 3700 participants consistently shows a small clinical benefit for memantine versus placebo, suggesting that memantine is not beneficial as a treatment for agitation.
Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment: a critical review
TLDR
Functional magnetic resonance imaging is powerful enough to detect even subtle changes over a short period of treatment; however, the soundness of methods should be improved to enable meaningful data interpretation.
Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment
TLDR
The CCCDTD has provided evidence‐based recommendations for diagnosis and management of VCI for use nationally in Canada, that may also be of use worldwide.
Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis
TLDR
Interestingly, the ADAS-cog and MMSE varied considerably in detecting cognitive improvement, and the therapeutic benefits of donepezil and galantamine in patients with vascular dementia are revealed.
Adequacy of Using Consensus Guidelines for Diagnosis of Dementia with Lewy Bodies in Clinical Trials for Drug Development
TLDR
Employing the consensus criteria for dementia with Lewy bodies (DLB) to enrol homogeneous DLB patients into future clinical trials regardless of the specialty of centres and time is adequate.
Management of mild cognitive impairment (MCI): The need for national and international guidelines
  • S. Kasper, C. Bancher, +7 authors M. Palomo
  • Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2020
TLDR
MCI is recognised as an important treatment target and some recent national guidelines have considered symptomatic treatment recommendations for MCI, however, more needs to be done, especially at an international level.
Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review
TLDR
The diverse aspects of AChEIs, including the mechanisms of action, characteristics and risk factors of ADRs, and preventive strategies of their ADRs are recapitulate and update.
Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
TLDR
Memantine monotherapy or combined with AChEIs are associated with more rapid cognitive and functional decline than non-users, and a potential selection bias by indication is postulated.
Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
TLDR
This article reviews the principal pharmacological intervention studies for Frontotemporal dementia and concludes that there is insufficient evidence on effective treatments for FTD and studies with better methodological backgrounds are needed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 271 REFERENCES
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology
TLDR
There is no clear evidence that any intervention can prevent or delay the onset of dementia, and the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
TLDR
Although the consensus statement dealt largely with medication, the role of dementia care in secondary services (geriatric medicine and old age psychiatry) and primary care, along with health economics, was discussed.
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
TLDR
Patients with DLB or PDD might benefit from treatment with memantine, which was well tolerated, and large-scale studies are now required to confirm the preliminary findings.
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
TLDR
This international guideline on dementia covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician, and revised the recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography, and cerebrospinal fluid analysis.
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
TLDR
In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate AD on stable ChEI regimens.
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis
  • Huifu Wang, J. Yu, +6 authors L. Tan
  • Psychology, Medicine
    Journal of Neurology, Neurosurgery & Psychiatry
  • 2014
TLDR
Cholinesterase inhibitors and memantine slightly improve global impression; however, only cholines terase inhibitors enhance cognitive function.
Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study
TLDR
In the present preliminary study, 16 dementia patients were prospectively categorized as having DLB versus AD, and patients categorized by EMG as EPS positive attained an increase in their mean MMSE score from baseline to 6 months that differed significantly from a decline in MMSE observed among their EPS negative counterparts.
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
TLDR
Data are insufficient to support widespread use of these drugs in vascular dementia, and individual patient analyses are needed to identify subgroups of patients with vascular dementia who might benefit.
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
  • M. Emre, M. Tsolaki, +7 authors Roy Jones
  • Psychology, Medicine
    The Lancet Neurology
  • 2010
BACKGROUND Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data
Guidelines for the Treatment of Alzheimer’s Disease from the Italian Association of Psychogeriatrics
TLDR
A committee of experts from the Italian Association of Psychogeriatrics compiled the following guidelines, based on a comprehensive review of the scientific literature on the treatment of Alzheimer’s disease, which discusses methodological aspects of dementia management, and details the limitations of current therapies.
...
1
2
3
4
5
...